Patient-reported outcomes after cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: A systematic review

Cancer Treatment Reviews

Volumn 36, Issue 6, 2010, Pages 501-506

  Colloca, Giuseppe ^a   Venturino, Antonella ^a   Checcaglini, Franco ^b  

^a ASL 1 Imperiese   (Italy)

^b ASL 1 Umbria   (Italy)

Author keywords

Chemotherapy; Health related quality of life; Pain; Patient related outcomes; Prostate cancer

Indexed keywords

CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; HYDROCORTISONE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISONE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASTRATION; DRUG CYTOTOXICITY; HEALTH STATUS; HUMAN; MALE; METASTASIS; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SHORT FORM 36; SURVIVAL; SYSTEMATIC REVIEW; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; PALLIATIVE THERAPY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CASTRATION; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PALLIATIVE CARE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 77956343050     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.02.001     Document Type: Review

References (47)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Newschaffer C.J., Otani K., McDonald M.K., et al. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 2000, 92:613-621.
3. Scher H.I., Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 2000, 55:323-327.
4. van Kleffens T., Van Baarsen B., Hoekman K., et al. Clarifying the term 'palliative' in clinical oncology. Eur J Cancer Care 2004, 13:263-271.
5. Petrylak D.P., Tangen C.M., Maha P.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
6. Tannock I.F., De Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
7. Hamberg P., Verhagen P.C., de Wit R. When to start cytotoxic therapy in asymptomatic patient with hormone refractory prostate cancer?. Eur J Cancer 2008, 44:1193-1197.
8. Schnadig I.D., Beer T.M. Optimal timing of chemotherapy in androgen independent prostate cancer. Urol Oncol 2009, 27:97-100.
9. Lipscomb J., Gotay C.C., Snyder C.E. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin 2007, 57:278-300.
10. Acquadro C., Berzon R., Dubois D., et al. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the food and drug administration. February 16, 2001. Value Health 2003, 6:522-531.
11. Arpinelli F., Bamfi F. The FDA guidance for industry on PROs: the point of view of a pharmaceutical company. Health Qual Life Outcomes 2006, 4:85. 10.1186/1477-7525-4-85.
12. Yancik R. Cancer burden in the aged. An epidemiologic and demographic overview. Cancer 1997, 80:1273-1283.
13. Stephens R.J., Hopwood P., Girling D.J. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer 1999, 79:538-544.
14. Bottomley A., Vanvoorden V., Flechtner H., et al. The challenges and achievements involved in implementing quality of life research in cancer clinical trials. Eur J Cancer 2003, 39:275-285.
15. Joly F., Vardy J., Pintilie M., et al. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol 2007, 18:1935-1942.
16. Berthold D.R., Pond G.R., Roessner M., et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008, 14:2763-2767.
17. Berry D.L., Moinpour C.M., Jiang C.S., Pauler Ankerst D., Petrylak D.P., Vinson L.V., et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwestern oncology group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 2006, 24:2828-2835.
18. Abratt R.P., Brune D., Dimopoulos M.A., et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 2004, 15:1613-1621.
19. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999, 17:2506-2513.
20. Ernst D.S., Tannock I.F., Winquist E.W., et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003, 21:3335-3342.
21. Hudes G., Einhorn L., Ross E., et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier oncology group and fox chase network phase III trial. J Clin Oncol 1999, 17:3160-3166.
22. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996, 14:1756-1764.
23. Dawson N.A., Conaway M., Halabi S., et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma. Cancer 2000, 88:825-834.
24. Fossa S.D., Aaronson N., Calais da Silva F., et al. Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer. Eur Urol 1989, 16:335-339.
25. Moinpour C.M., Donaldson G.W. Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: dynamically modified outcomes (DYNAMO) analysis of a randomized controlled trial. Qual Life Res 2009, 18:147-155.
26. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 2008, 26:1148-1159.
27. Guyatt G.H., Osoba D., Wu A.W., et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002, 77:371-383.
28. Cella D., Nichol M.B., Eton D., Nelson J.B., Mulani P. Estimating clinically meaningful changes for the functional assessment of cancer therapy-prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 2009, 12:124-129.
29. Hjermstad M.J., Fayers P.M., Bjordal K., et al. Health-related quality of life in the general Norwegian population assessed by the European organization for research and treatment of cancer Coro quality-of-life questionnaire: the QLQ-C30. J Clin Oncol 1998, 16:1188-1196.
30. King M.T. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996, 5:555-567.
31. Curran D., Fossa S., Aaronson N., et al. Baseline quality of life of patients with advanced prostate cancer. European organization for research and treatment of cancer (EORTC), genito-urinary tract cancer cooperative group (GUT-CCG). Eur J Cancer 1997, 33:1809-1814.
32. Sommers S.D., Ramsey S.D. A review of quality-of-life evaluations in prostate cancer. Pharmacoeconomics 1999, 16:127-130.
33. Fitzsimmons D., Gilbert J., Howse F., et al. A systematic review of the use and validation of health-related quality of life instruments in older cancer patients. Eur J Cancer 2009, 45:19-32.
34. Lichtman S.M., Wildiers H., Chatelut E., et al. International society of geriatric oncology chemotherapy taskforce. Evaluation of chemotherapy in older patients - an analysis of the medical literature. J Clin Oncol 2007, 25:1832-1843.
35. Droz J.P., Chaladaj A. Management of metastatic prostate cancer: the crucial role of geriatric assessment. BJU Int 2008, 101(Suppl. 2):23-29.
36. Hurria A., Gupta S., Zauderer M., et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 2005, 104:1998-2005.
37. Tannenbaum C., Ahmed S., Mayo N. What drives older women's perceptions of health-related quality of life?. Qual Life Res 2007, 16:593-605.
38. Hickey A., Barker M., McGee H., et al. Measuring health-related quality of life in older patient populations: a review of current approaches. Pharmacoeconomics 2005, 23:971-993.
39. Butler J., Ciarrochi J. Psychological acceptance and quality of life in the elderly. Qual Life Res 2007, 16:607-615.
40. Kaasa S., Hjermstad M.J., Jordhoy M.S., et al. Compliance in quality of life data: a Norwegian experience. Stat Med 1998, 17:623-632.
41. Blazeby J.M., Avery K., Sprangers M., et al. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol 2006, 24:3178-3186.
42. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 1994, 12:608-616.
43. Gotay C.C., Kawamoto C.T., Bottomley A., et al. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008, 26:1355-1363.
44. Halabi S., Vogelzang N.J., Kornblith A.B., Ou S.S., Kantoff P.W., Dawson N.A., et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 2008, 26:2544-2549.
45. Armstrong A.J., Garrett-Mayer E., Yang Y.C.O., Carducci M.A., Tannock I., de Wit R., et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007, 25:3965-3970.
46. Kiecolt-Glaser J.K., Robles T.F., Heffner K.L., et al. Psycho-oncology and cancer: psychoneuroimmunology and cancer. Ann Oncol 2002, 13(Suppl. 4):165-169.
47. Rummans T.A., Clark M.M., Sloan J.A., et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol 2006, 24:635-642.